Cargando…
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
Autores principales: | Maruyama, Hiroki, Miyata, Kaori, Mikame, Mariko, Taguchi, Atsumi, Guili, Chu, Shimura, Masaru, Murayama, Kei, Inoue, Takeshi, Yamamoto, Saori, Sugimura, Koichiro, Tamita, Koichi, Kawasaki, Toshihiro, Kajihara, Jun, Onishi, Akifumi, Sugiyama, Hitoshi, Sakai, Teiko, Murata, Ichijiro, Oda, Takamasa, Toyoda, Shigeru, Hanawa, Kenichiro, Fujimura, Takeo, Ura, Shigehisa, Matsumura, Mimiko, Takano, Hideki, Yamashita, Satoshi, Matsukura, Gaku, Tazawa, Ryushi, Shiga, Tsuyoshi, Ebato, Mio, Satoh, Hiroshi, Ishii, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608386/ https://www.ncbi.nlm.nih.gov/pubmed/30190610 http://dx.doi.org/10.1038/s41436-018-0125-2 |
Ejemplares similares
-
Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2018) -
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2019) -
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2018) -
Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses
por: Baydakova, Galina, et al.
Publicado: (2020) -
Lyso-Gb3 modulates the gut microbiota and decreases butyrate production
por: Aguilera-Correa, John-Jairo, et al.
Publicado: (2019)